The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
When less is better: Safety and efficacy of combination of trastuzumab and continuous low oral dose chemotherapy (HEX) as first-line therapy for HER2-positive advanced breast cancer (ABC)—First early results from a phase II trial on behalf of Gruppo Oncologico Italia Meridionale (GOIM).
Laura Orlando
No relevant relationships to disclose
Francesco Giotta
No relevant relationships to disclose
Margherita Cinefra
No relevant relationships to disclose
Daniele Rizzi
No relevant relationships to disclose
Salvatore Pisconti
No relevant relationships to disclose
Salvatore Del Prete
No relevant relationships to disclose
Mariangela Ciccarese
No relevant relationships to disclose
Antonio Rinaldi
No relevant relationships to disclose
Paola Schiavone
No relevant relationships to disclose
Annamaria Quaranta
No relevant relationships to disclose
Palma Fedele
No relevant relationships to disclose
Angelo Nacci
No relevant relationships to disclose
Nicola Calvani
No relevant relationships to disclose
Vito Lorusso
No relevant relationships to disclose
Giuseppe Colucci
No relevant relationships to disclose
Saverio Cinieri
No relevant relationships to disclose